Patient Case 2: The Threshold for Switching Therapies

Experts agree the threshold for changing therapy is clear in this case, driven by two major factors. First, the skin is not controlled, with a Body Surface Area (BSA) of 8%, well above the treat-to-target goal of 3% or less. Second, and more urgently, the patient has uncontrolled and likely progressive psoriatic arthritis (PsA) symptoms.

The breaking point for action is the presence of active joint disease, which can cause irreversible damage. PsA is a heterogeneous condition requiring a systemic approach. The consensus is to act promptly from the dermatology side, initiating or switching to a therapy that comprehensively addresses both skin and joint inflammation. This immediate intervention is crucial, even if a future rheumatology consultation will help refine long-term management. The goal is to start effective systemic control without delay.